An analysis of previously published studies shows greater reductions in LDL ("bad") cholesterol using Vytorin, whose formula includes Zocor, than using Zocor alone. Schering-Plough, manufacturer of Vytorin, says its medication reduces LDL cholesterol by an average of 52.5 percent, compared with 31 percent for Zocor.
Read moreAnother week, another set of studies calling into question the benefits and risks of a widely used drug. This time it's Vytorin, a... Read more »
The makers of Vytorin®, Merck/Schering-Plough Pharmaceuticals, recently issued a controversial press release about the Enhance Study that... Read more »
The combination drug Vytorin, which includes anti-cholesterol drugs Zetia and Zocor, does not result in greater risk of muscle damage than Zocor... Read more »
New research has found that the combination cholesterol med Vytorin is no more effective than a high dose of one of its components that's available... Read more »
Patients taking Vytorin are more likely to reduce their LDL ("bad") cholesterol than those taking Lipitor, says Schering-Plough, maker of Vytorin.... Read more »
Drugmakers Merck and Schering-Plough are teaming up to make a new combination cholesterol medication that will compete with Vytorin. Vytorin is a... Read more »
Vytorin lowers bad cholesterol more effectively than Liptor in patients who have both Type 2 diabetes and high cholesterol, a new study has found.... Read more »